Protara Therapeutics Completes First Cohort Of Phase 2 STARBORN-1 Trial For TARA-002 In Pediatric Lymphatic Malformations; Enrollment Ongoing In Additional Cohorts With Initial Results Expected In 1H 2025
Author: Benzinga Newsdesk | September 09, 2024 08:08am